706 related articles for article (PubMed ID: 24602049)
21. Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study.
Sridharan K; Modi T; Bendkhale S; Kulkarni D; Gogtay NJ; Thatte UM
Curr Clin Pharmacol; 2016; 11(1):62-8. PubMed ID: 26777610
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support.
Awad M; Czer LS; Soliman C; Mirocha J; Ruzza A; Pinzas J; Rihbany K; Chang D; Moriguchi J; Ramzy D; Esmailian F; Kobashigawa J; Arabia F
ASAIO J; 2015; 61(4):391-6. PubMed ID: 26125664
[TBL] [Abstract][Full Text] [Related]
23. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
[TBL] [Abstract][Full Text] [Related]
24. Improvements in CYP2C9 Genotyping Accuracy Are Needed: A Report of the First Proficiency Testing for Warfarin-related CYP2C9 and VKORC1 Genotyping in China.
Lin G; Yi L; Zhang K; Sun Y; Wang L; Zhang R; Xie J; Li J
J Cardiovasc Pharmacol; 2015 Aug; 66(2):129-34. PubMed ID: 25815675
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
[TBL] [Abstract][Full Text] [Related]
26. Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.
Abohelaika S; Wynne H; Avery P; Kampouraki E; Kamali F
Thromb Res; 2018 Nov; 171():167-170. PubMed ID: 30321703
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
Farzamikia N; Sakhinia E; Afrasiabirad A
Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
[TBL] [Abstract][Full Text] [Related]
28. Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.
Molden E; Okkenhaug C; Ekker Solberg E
Eur J Clin Pharmacol; 2010 May; 66(5):525-30. PubMed ID: 20354686
[TBL] [Abstract][Full Text] [Related]
29. VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.
Azzam H; Elwakeel H; Awad I; El-Farahaty R; El-Gilany AH; El-Sharawy S
Blood Coagul Fibrinolysis; 2016 Mar; 27(2):121-6. PubMed ID: 24978953
[TBL] [Abstract][Full Text] [Related]
30. Association between HNF4A mutations and bleeding complications in patients with stable international normalized ratio.
Kim W; Yee J; Chang BC; Chung JE; Lee KE; Gwak HS
Pharmacogenet Genomics; 2019 Oct; 29(8):200-206. PubMed ID: 31461081
[TBL] [Abstract][Full Text] [Related]
31. Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients.
Zhang S; Zhao M; Zhong S; Niu J; Zhou L; Zhu B; Su H; Cao W; Xing Q; Yan H; Han X; Fu Q; Li Q; Chen L; Yang F; Zhang N; Wu H; He L; Qin S
Pharmacogenet Genomics; 2024 Jun; 34(4):105-116. PubMed ID: 38470454
[TBL] [Abstract][Full Text] [Related]
32. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
33. Cytochrome P450 (CYP2C9*2,*3) & vitamin-K epoxide reductase complex (VKORC1 -1639GKaur A; Khan F; Agrawal SS; Kapoor A; Agarwal SK; Phadke SR
Indian J Med Res; 2013 Jan; 137(1):203-9. PubMed ID: 23481074
[TBL] [Abstract][Full Text] [Related]
34. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
[TBL] [Abstract][Full Text] [Related]
35. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
[TBL] [Abstract][Full Text] [Related]
36. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population.
Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T
Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616
[TBL] [Abstract][Full Text] [Related]
37. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
[TBL] [Abstract][Full Text] [Related]
38. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan MF; Foad DA; Darwish YW; Saad AA
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
[TBL] [Abstract][Full Text] [Related]
39. Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy.
Eriksson N; Wallentin L; Berglund L; Axelsson T; Connolly S; Eikelboom J; Ezekowitz M; Oldgren J; Paré G; Reilly P; Siegbahn A; Syvanen AC; Wadelius C; Yusuf S; Wadelius M
Pharmacogenomics; 2016 Aug; 17(13):1425-39. PubMed ID: 27488176
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]